Fast ex-Flexus team takes Arcus to a quick $100M IPO to advance I/O pipeline
The fast-moving team at Arcus has filed for an $100 million IPO, looking to build its immuno-oncology pipeline of small molecules and antibody compounds under the leadership of co-founder Terry Rosen.
Expected to fund the clinical development of lead product candidates AB928 and AB122 into 2020, this round of fundraising follows a $107 million Series C crossover completed just last November. AB928 is a dual adenosine receptor antagonist, while AB122 is a PD-1 antibody. Arcus had scheduled a Phase I/II trial to test the combo in cancer patients for the first half of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.